The Neuropathology Core for this Program Project Grant is a laboratory function dervied from neurohistochemistry and imunostaining capabilities that currently exist in the research laboratories of Drs. Davidson and Moore. Formalization of this laboratory function as the Neuropathology Core housed within Dr. Moore's research laboratory will centralize personnel, equipment, and reagents necessary to efficiently produce high quality brain sections and stains ready for microscopic evaluaton. The Neuropathology Core facility's overall objective is to support Drs. Davidson, Paulson, Kosik, Gonzalez-Alegre, and Dauer in the evaluation of mouse brains following transduction with viruses expressing specific shRNAs. This includes consultation with Program investigators concerning the processing of brains for microscopic evaluation, development of specific immunostaining or histochemical staining protocols, production of high quality brain sections, and staining sections for evaluation in individual investigator laboratories. The Neuropathology Core staff and investigators are in close contact through all phases of this process. Thus, the Core serves as both a research and development facility for histology-based methods and a service facility to provide brain sections ready for microscopic evaluation. In addition, Dr. Moore (a board-certified neuropathologist) will provide standard neuropathologic evaluation of brain sections as needed for each project. This latter responsibility is particularly important in the objective evaluation of transduced brains for untoward effects of RNAi. The main responsibilities of the Core will be: 1) Complete the processing of brains for histologic evaluation; 2) Produce microscopic sections specifically adapted to the needs of each project; 3) Produce histochemical or immunostained slides as needed by each project; 4) Store uncut tissue and unstained sections; 5) Evaluate brains for general neuropathological changes as needed by each project; 6) Develop new staining methods for use in individual projects.
| Lee, John H; Tecedor, Luis; Chen, Yong Hong et al. (2015) Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes. Neuron 85:303-15 |
| Monteys, Alex Mas; Spengler, Ryan M; Dufour, Brett D et al. (2014) Single nucleotide seed modification restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse brain. Nucleic Acids Res 42:13315-27 |
| Ramachandran, Pavitra S; Boudreau, Ryan L; Schaefer, Kellie A et al. (2014) Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7. Mol Ther 22:1635-42 |
| Ramachandran, Pavitra S; Bhattarai, Sajag; Singh, Pratibha et al. (2014) RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration. PLoS One 9:e95362 |
| Lee, John H; Sowada, Matthew J; Boudreau, Ryan L et al. (2014) Rhes suppression enhances disease phenotypes in Huntington's disease mice. J Huntingtons Dis 3:65-71 |
| Boudreau, Ryan L; Jiang, Peng; Gilmore, Brian L et al. (2014) Transcriptome-wide discovery of microRNA binding sites in human brain. Neuron 81:294-305 |
| Rodríguez-Lebrón, Edgardo; Costa, Maria do Carmo; Costa, Maria doCarmo et al. (2013) Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol Ther 21:1909-18 |
| Costa, Maria do Carmo; Luna-Cancalon, Katiuska; Fischer, Svetlana et al. (2013) Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. Mol Ther 21:1898-908 |
| Ramachandran, Pavitra S; Keiser, Megan S; Davidson, Beverly L (2013) Recent advances in RNA interference therapeutics for CNS diseases. Neurotherapeutics 10:473-85 |
| Boudreau, Ryan L; Spengler, Ryan M; Hylock, Ray H et al. (2013) siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Res 41:e9 |
Showing the most recent 10 out of 35 publications
